Literature DB >> 7523671

Autoimmune sera react with multiple epitopes on recombinant 52 and 60 kDa Ro(SSA) proteins.

D P McCauliffe1, H Yin, L X Wang, L Lucas.   

Abstract

OBJECTIVE: To determine the reactivity of recombinant 52 and 60 kDa Ro(SSA) (Ro) proteins with sera from 3 subsets of patients with Ro autoantibody associated disease.
METHODS: Complementary DNA (cDNA) clones that encode the human 52 and 60 kDa Ro autoantigens were isolated by the polymerase chain reaction and utilized to express recombinant glutathione S-transferase (GST) fusion proteins. Double immunodiffusion (ID) defined Ro positive autoimmune sera from 12 patients with neonatal lupus erythematosus (NLE), 16 with subacute cutaneous lupus erythematosus (SCLE) and 12 with primary Sjögren's syndrome (SS) were tested by enzyme linked immunosorbent assay (ELISA) against the recombinant 52 and 60 kDa Ro fusion proteins.
RESULTS: Seventy-five percent of NLE, 56% of SCLE and 83% of SS sera reacted with the 52 kDa fusion protein. Seventy-five percent of NLE, 63% of SCLE and 83% of SS sera reacted with the 60 kDa fusion protein. Seventeen percent of NLE sera, 25% of SCLE sera and 8% of SS sera were nonreactive to both full length fusion proteins. Eight (57%) of 14 ID defined Ro negative NLE, SCLE and SS sera were reactive with both Ro fusion proteins by ELISA: ELISA studies with recombinant 52 and 60 kDa Ro protein fragments revealed at least 2 major epitopes on each Ro protein. A fragment of the 52 kDa Ro protein that contains a putative leucine zipper motif reacted with 100% of ID defined Ro positive SS sera.
CONCLUSION: Our data demonstrate that the ID assay and the recombinant Ro ELISA together are more sensitive in detecting Ro antibodies than either assay alone, and that multiple epitopes are present on both Ro proteins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523671

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Identification and management of fetuses at risk for, or affected by, congenital heart block associated with autoantibodies to SSA (Ro), SSB (La), or an HsEg5-like autoantigen.

Authors:  Renate Claus; Heiko Hickstein; Thomas Külz; Ute Lenschow; Doris Meiske; Andrea Kotitschke; Hans-Jürgen Thiesen; Peter Lorenz
Journal:  Rheumatol Int       Date:  2006-01-10       Impact factor: 2.631

Review 2.  Sjögren's syndrome--study of autoantigens and autoantibodies.

Authors:  John G Routsias; Athanasios G Tzioufas
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

3.  Modeling of main characteristics of bullous pemphigoid antigen-2 (BPAG2) peptide structure in serological recognition by autoantibodies.

Authors:  József Pál; Ilona Marczinovits; Ferenc Hudecz; Gábor K Tóth; Gábor Mezõ; János Molnár; Péter Németh
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

Review 4.  Ro/SS-A and La/SS-B: autoantigens in Sjögren's syndrome?

Authors:  R J Smeenk
Journal:  Clin Rheumatol       Date:  1995-07       Impact factor: 2.980

Review 5.  Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis.

Authors:  Edward K L Chan
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-18       Impact factor: 10.817

6.  Clinical significances of antibodies to Ro/SS-A autoantigens and its subtypes in primary Sjögren's syndrome.

Authors:  C S Cho; S H Park; J K Min; S H Lee; H Y Kim
Journal:  Korean J Intern Med       Date:  1997-06       Impact factor: 2.884

7.  Anti-Ro60 Seropositivity Determines Anti-Ro52 Epitope Mapping in Patients With Systemic Sclerosis.

Authors:  Athanasios Gkoutzourelas; Christos Liaskos; Maria G Mytilinaiou; Theodora Simopoulou; Christina Katsiari; Alexandra Tsirogianni; Dimitrios Daoussis; Thomas Scheper; Wolfgang Meyer; Dimitrios P Bogdanos; Lazaros I Sakkas
Journal:  Front Immunol       Date:  2018-12-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.